Structure Therapeutics (NASDAQ:GPCR) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a hold rating to a sell rating in a research report report published on Saturday morning.

A number of other equities analysts have also recently issued reports on GPCR. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. HC Wainwright increased their price objective on shares of Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Stifel Nicolaus boosted their target price on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $104.45.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $89.84 on Friday. The firm’s fifty day moving average price is $67.32 and its two-hundred day moving average price is $39.70. The stock has a market cap of $5.45 billion, a PE ratio of -73.64 and a beta of -2.07. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, sell-side analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. lifted its stake in Structure Therapeutics by 7.2% during the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after purchasing an additional 106,389 shares during the last quarter. Casdin Capital LLC lifted its position in Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after buying an additional 330,000 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after buying an additional 496,726 shares in the last quarter. Millennium Management LLC grew its position in Structure Therapeutics by 4.5% during the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares during the last quarter. Finally, Orbimed Advisors LLC grew its position in Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after acquiring an additional 397,272 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.